An early phase 2 study with XELODA™ (capecitabine) in patients with metastatic breast cancer

被引：0
|
作者：
Saeki, T
Takashima, S
Terashima, M
Tabei, T
Enomoto, K
Tominaga, T
Kimura, T
Miura, S
Koyama, H
Konishi, Y
Oka, T
Naito, Y
Sonoo, H
Toge, T
Dohi, K
Nomizu, T
Taguchi, T
机构：
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
594
引用
收藏
页码：155 / 155
页数：1
相关论文
共 50 条
  • [1] Photoeruption in a patient treated with capecitabine (Xeloda) for metastatic breast cancer
    Willey, A
    Glusac, EJ
    Bolognia, JL
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (03) : 453 - 453
  • [2] Optimizing the management of HER2-negative metastatic breast cancer with capecitabine (Xeloda)
    Leonard, R
    Miles, D
    Reichardt, P
    Twelves, C
    SEMINARS IN ONCOLOGY, 2004, 31 (05) : 21 - 28
  • [3] Usefulness of Xeloda, capecitabine for metastatic breast cancer (MBC) In the ambulatory practice
    Rodger, J
    Mickiewicz, E
    Giacomi, N
    Vigo, S
    Tatangelo, M
    Formiels, H
    Coppola, F
    Jovtis, S
    Lastiri, F
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
  • [4] Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer
    Reigner, B
    Watanabe, T
    Schüller, J
    Lucraft, H
    Sasaki, Y
    Bridgewater, J
    Saeki, T
    McAleer, J
    Kuranami, M
    Poole, C
    Kimura, M
    Monkhouse, J
    Yorulmaz, C
    Weidekamm, E
    Grange, S
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (03) : 193 - 201
  • [5] Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer
    Bruno Reigner
    Toru Watanabe
    Johannes Schüller
    Helen Lucraft
    Yasutsuna Sasaki
    John Bridgewater
    Toshiaki Saeki
    James McAleer
    Masaru Kuranami
    Christopher Poole
    Mitsunori Kimura
    Jayne Monkhouse
    Cahit Yorulmaz
    Erhard Weidekamm
    Susan Grange
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 193 - 201
  • [6] Dose-finding phase I and pharmacokinetic study of capecitabine (xeloda) in combination with epirubicin and cyclophosphamide (CEX) in patients with inoperable or metastatic breast cancer
    Saji, Shigehira
    Toi, Masakazu
    Morita, Satoshi
    Iwata, Hiroji
    Ito, Yoshinori
    Ohno, Shinji
    Kobayashi, Tadashi
    Hozumi, Yasuo
    Sakamoto, Junichi
    ONCOLOGY, 2007, 72 (5-6) : 330 - 337
  • [7] Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
    Reichardt, P
    von Minckwitz, G
    Thuss-Patience, PC
    Jonat, W
    Kölbl, H
    Jänicke, F
    Kieback, DG
    Kuhn, W
    Schindler, AE
    Mohrmann, S
    Kaufmann, M
    Lück, HJ
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1227 - 1233
  • [8] Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
    D C Talbot
    V Moiseyenko
    S Van Belle
    S M O'Reilly
    E Alba Conejo
    S Ackland
    P Eisenberg
    D Melnychuk
    T Pienkowski
    H-U Burger
    S Laws
    B Osterwalder
    British Journal of Cancer, 2002, 86 : 1367 - 1372
  • [9] Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines
    Talbot, DC
    Moiseyenko, V
    Van Belle, S
    O'Reilly, SM
    Conejo, EA
    Ackland, S
    Eisenberg, P
    Melnychuk, D
    Pienkowski, T
    Burger, HU
    Laws, S
    Osterwalder, B
    BRITISH JOURNAL OF CANCER, 2002, 86 (09) : 1367 - 1372
  • [10] Phase II study of capecitabine (Xeloda®)in combination with paclitaxel (P) in the treatment of patients with locally advanced or metastatic breast cancer (BC):: Preliminary results.
    Batista, N
    Manga, GP
    Constenla, M
    Guillem, V
    Carabantes, F
    Ahlgren, J
    Castellanos, J
    Barón, MG
    Villman, K
    Söderberg, M
    Casinello, J
    Murias, A
    Regueiro, P
    ANNALS OF ONCOLOGY, 2000, 11 : 32 - 32
12345